Equities
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,514.00
  • Today's Change-15.50 / -1.01%
  • Shares traded486.05k
  • 1 Year change-31.09%
  • Beta0.2869
Data delayed at least 20 minutes, as of Dec 05 2022 16:35 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Key statistics

On Monday, Hikma Pharmaceuticals PLC (HIK:LSE) closed at 1,514.00, 28.91% above the 52 week low of 1,174.50 set on Oct 24, 2022.
52-week range
Today
1,174.50Oct 24 20222,294.00Dec 07 2021
Markit short selling activity
Low
Med
High
Open1,531.00
High1,558.00
Low1,514.00
Bid1,195.00
Offer1,517.50
Previous close1,514.00
Average volume600.65k
Shares outstanding220.23m
Free float154.80m
P/E (TTM)12.42
Market cap3.36bn GBP
EPS (TTM)1.23
GBP
Annual div (ADY)44.24
GBX
Annual div yield (ADY)2.89%
Div ex-dateAug 18 2022
Div pay-dateSep 20 2022
Data delayed at least 20 minutes, as of Dec 05 2022 16:35 GMT.
More ▼

Investors Chronicle View

The last IC recommendation on Hikma Pharmaceuticals PLC shares was Buy at 1.00 on 04 Aug 2022Read the full article

Board of Directors

1/9

Said Darwazah, Executive Chairman and CEO

2/9

Mazen Darwazah, Executive Vice Chairman, President of MENA

3/9

Ali Al-Husry, Non-Executive Director

4/9

Pat Butler, Nomination and Governance Committee Chairman, Senior Independent Non-Executive Director

5/9

John Castellani, CREC Chairman, Independent Non-Executive Director

6/9

Nina Henderson, Remuneration Committee Chairman, Independent Non-Executive Director

7/9

Cynthia Flowers, Independent Non-Executive Director

8/9

Douglas Hurt, Audit Committee Chairman, Independent Non-Executive Director

9/9

Hussein Arkhagha, Chief Counsel and Company Secretary

Contact

Address:
Hikma Pharmaceuticals PLC
1 New Burlington Place
London
W1S 2HR

T: +44 (0) 20 7399 2760
F: +44 (0) 20 7399 2761
E: investors@hikma.uk.com
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.